SIPA1 Is a Modulator of HGF/MET Induced Tumour Metastasis Via the Regulation of Tight Junction-Based Cell to Cell Barrier Function

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 30

PMID 33917539

Citations 5

Authors

Chang Liu

Wenguo Jiang

Lijian Zhang

Rachel Hargest

Tracey A Martin

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is the leading cause of cancer death. SIPA1 is a mitogen induced GTPase activating protein (GAP) and may hamper cell cycle progression. SIPA1 has been shown to be involved in MET signaling and may contribute to tight junction (TJ) function and cancer metastasis.

Methods: Human lung tumour cohorts were analyzed. In vitro cell function assays were performed after knock down of SIPA1 in lung cancer cells with/without treatment. Quantitative polymerase chain reaction (qPCR) and western blotting were performed to analyze expression of HGF (hepatocyte growth factor), MET, and their downstream markers. Immunohistochemistry (IHC) and immunofluorescence (IFC) staining were performed.

Results: Higher expression of SIPA1 in lung tumours was associated with a poorer prognosis. Knockdown of SIPA1 decreased invasiveness and proliferation of in vitro cell lines, and the SIPA1 knockdown cells demonstrated leaky barriers. Knockdown of SIPA1 decreased tight junction-based barrier function by downregulating MET at the protein but not the transcript level, through silencing of Grb2, SOCS, and PKCμ (Protein kinase Cµ), reducing the internalization and recycling of MET. Elevated levels of SIPA1 protein are correlated with receptor tyrosine kinases (RTKs), especially HGF/MET and TJs. The regulation of HGF on barrier function and invasion required the presence of SIPA1.

Conclusions: SIPA1 plays an essential role in lung tumourigenesis and metastasis. SIPA1 may be a diagnostic and prognostic predictive biomarker. SIPA1 may also be a potential therapeutic target for non-small cell lung cancer (NSCLC) patients with aberrant MET expression and drug resistance.

Citing Articles

SIPA1 promotes epithelial-mesenchymal transition in colorectal cancer through STAT3 activation.

Li Y, Wang M, Jiang L, Jia J, Pan F, Li W Heliyon. 2024; 10(14):e34527.

PMID: 39130435 PMC: 11315193. DOI: 10.1016/j.heliyon.2024.e34527.

SIPA1 promotes angiogenesis by regulating VEGF secretion in Müller cells through STAT3 activation.

Fang Y, Wang Q, Zhang L, Xie L Heliyon. 2024; 10(2):e24869.

PMID: 38312659 PMC: 10834823. DOI: 10.1016/j.heliyon.2024.e24869.

A novel transcription factor SIPA1: identification and verification in triple-negative breast cancer.

Guo L, Zhang W, Zhang X, Wang J, Nie J, Jin X Oncogene. 2023; 42(35):2641-2654.

PMID: 37500797 PMC: 10457189. DOI: 10.1038/s41388-023-02787-3.

SIPA1 Regulates LINC01615 to Promote Metastasis in Triple-Negative Breast Cancer.

Xiang Y, Feng L, Liu H, Liu Y, Li J, Su L Cancers (Basel). 2022; 14(19).

PMID: 36230738 PMC: 9562673. DOI: 10.3390/cancers14194815.

Extracellular Vesicles Derived from SIPA1 Breast Cancer Cells Enhance Macrophage Infiltration and Cancer Metastasis through Myosin-9.

Feng L, Weng J, Yao C, Wang R, Wang N, Zhang Y Biology (Basel). 2022; 11(4).

PMID: 35453742 PMC: 9032110. DOI: 10.3390/biology11040543.

References

Brooks R, Kizer N, Nguyen L, Jaishuen A, Wanat K, Nugent E . Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol. 2009; 116(3):539-43. PMC: 2822070. DOI: 10.1016/j.ygyno.2009.09.037. View

Jiang W, Martin T, Matsumoto K, Nakamura T, Mansel R . Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J Cell Physiol. 1999; 181(2):319-29. DOI: 10.1002/(SICI)1097-4652(199911)181:2<319::AID-JCP14>3.0.CO;2-S. View

Gdowicz-Klosok A, Giglok M, Drosik A, Suwinski R, Butkiewicz D . The SIPA1 -313A>G polymorphism is associated with prognosis in inoperable non-small cell lung cancer. Tumour Biol. 2014; 36(2):1273-8. DOI: 10.1007/s13277-014-2753-8. View

Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot A, Copin M . The multiple paths towards MET receptor addiction in cancer. Oncogene. 2018; 37(24):3200-3215. DOI: 10.1038/s41388-018-0185-4. View

Trusolino L, Bertotti A, Comoglio P . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010; 11(12):834-48. DOI: 10.1038/nrm3012. View

Chen Z, Fillmore C, Hammerman P, Kim C, Wong K . Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14(8):535-46. PMC: 5712844. DOI: 10.1038/nrc3775. View

Martin T, Lane J, Harrison G, Jiang W . The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis. PLoS One. 2014; 8(12):e82696. PMC: 3873263. DOI: 10.1371/journal.pone.0082696. View

Li J, Wang J, Liu C, Ma D, Ma J . Dynamic relationship between SIPA1 gene and protein expression and the development of gastric cancer. Genet Mol Res. 2017; 16(1). DOI: 10.4238/gmr16019271. View

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12):915-25. DOI: 10.1038/nrm1261. View

10.

Wu Y, Soo R, Locatelli G, Stammberger U, Scagliotti G, Park K . Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. Cancer Treat Rev. 2017; 61:70-81. DOI: 10.1016/j.ctrv.2017.10.003. View

11.

Martin T, Mansel R, Jiang W . Antagonistic effect of NK4 on HGF/SF induced changes in the transendothelial resistance (TER) and paracellular permeability of human vascular endothelial cells. J Cell Physiol. 2002; 192(3):268-75. DOI: 10.1002/jcp.10133. View

12.

Ma P, Jagadeeswaran R, Jagadeesh S, Tretiakova M, Nallasura V, Fox E . Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005; 65(4):1479-88. DOI: 10.1158/0008-5472.CAN-04-2650. View

13.

Martin T, Watkins G, Mansel R, Jiang W . Hepatocyte growth factor disrupts tight junctions in human breast cancer cells. Cell Biol Int. 2004; 28(5):361-71. DOI: 10.1016/j.cellbi.2004.03.003. View

14.

Jamal-Hanjani M, Wilson G, McGranahan N, Birkbak N, Watkins T, Veeriah S . Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(22):2109-2121. DOI: 10.1056/NEJMoa1616288. View

15.

Martin T, Jiang W . Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2008; 1788(4):872-91. DOI: 10.1016/j.bbamem.2008.11.005. View

16.

Jiang W, Hiscox S, Parr C, Martin T, Matsumoto K, Nakamura T . Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res. 1999; 5(11):3695-703. View

17.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

18.

Lemmon M, Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2010; 141(7):1117-34. PMC: 2914105. DOI: 10.1016/j.cell.2010.06.011. View

19.

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G . Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89-103. DOI: 10.1038/nrc3205. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View